New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
pharmafile | April 30, 2019 | News story | Manufacturing and Production, Research and Development | Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment of moderate-to-severe plaque psoriasis, and its efficacy in patients showing signs of psoriasis-related nail disease and those showed an inadequate early treatment response to the drug.
The first 96 weeks of data derived from 995 participants across two ongoing Phase 3 studies demonstrated that “confirmed the long-term safety of Cimzia in the treatment of psoriasis”, with no new safety concerns flagged, while the overall incidence of adverse events was low.
Additionally, pooled 48-week data from the two studies showed that 66% of psoriasis patients with nail disease achieved total resolution, with results consistent on either regimen and with similar efficacy in patients with and without concomitant psoriatic arthritis.
The data also demonstrated that, in patients who responded partially or inadequately in the first 16 weeks of treatment, Cimzia produced an improvement in PASI75, PASI90 and PGA 0/1 response rates over an additional 32 weeks of treatment with 400mg every two weeks.
“This new research demonstrates UCB’s ongoing commitment to delivering meaningful outcomes for psoriasis patients, where there is still significant unmet need,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB. “This includes patients with psoriatic nail disease and those who do not initially adequately respond to their treatment dose. The multitude of evidence from these ongoing trials complements data from across all areas of chronic inflammatory diseases to show the value of Cimzia in treating different patient populations.”
Matt Fellows
Related Content
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
